Endpoints in lung cancer trials: today’s challenges for clinical statistics
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://link.springer.com/content/pdf/10.1007/s12254-013-0082-z.pdf
Reference34 articles.
1. Pilz LR, Manegold C, Schmid-Bindert G. Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small cell lung cancer? Transl Lung Cancer Res. 2012;1(1):26–35.
2. Klein PJ, Goel PK (eds.). Survival analysis: State of the art. Dordrecht: Kluwer Academic Publisher; 1992.
3. Klein PJ, Moeschberger ML. Survival analysis. Techniques for censored and truncated data. 2nd ed. New York: Springer-Verlag; 2003.
4. Rosenberger WF, Lachin JM. Randomization in clinical trials: Theory and practice. New York: John Wiley & Sons; 2002.
5. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. Brit Med J. 2000;321(7259):504.
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Basic Statistics and Clinical Studies in Radiation Oncology;Radiation Oncology;2018
2. YI01a.02 Basic Statistical Considerations;Journal of Thoracic Oncology;2017-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3